Poor
Not Aligned
Patient Risk:
High
Summary
Many non-label claims are included (pricing, coupons, patent status, generic availability, alternative drugs, and several generalized statements). Label-specific content on indication and mechanism is largely consistent, but there are material dosing/administration and safety-warning omissions relative to the label, and multiple claims are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Silodosin works by selectively blocking alpha-1A adrenergic receptors.
Label 12.1: “Silodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors…” (supports alpha-1 selective antagonist mechanism). Supplied label excerpt does not explicitly say alpha-1A, but aligns with selective alpha-1 mechanism described.
By relaxing smooth muscle in the prostate gland, bladder neck, and urethra, Silodosin improves urine flow.
Label 12.1: “Blockade… can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.”
By relaxing smooth muscle in the prostate gland, bladder neck, and urethra, Silodosin reduces the symptoms of BPH.
Label 12.1: “...resulting in an improvement in urine flow and a reduction in BPH symptoms.”
Unsupported Statements
The price of Silodosin tablets can vary depending on dosage, quantity, and the pharmacy or online retailer.
Not addressed in the supplied prescribing information.
Generic versions of Silodosin are available.
Not addressed in the supplied prescribing information.
Generic Silodosin generally offers a lower cost compared to brand-name options.
Not addressed in the supplied prescribing information.
A 30-count bottle of 8 mg Silodosin tablets might range from approximately $20 to over $100.
Not addressed in the supplied prescribing information.
The cost of a prescription for Silodosin can range from around $20 to over $100 for a 30-day supply.
Not addressed in the supplied prescribing information.
The cost depends on the specific dosage and whether a generic or brand-name product is dispensed.
Not addressed in the supplied prescribing information.
Insurance coverage, pharmacy pricing, and available coupons or discount programs can influence the out-of-pocket expense for patients.
Not addressed in the supplied prescribing information.
Discounts on Silodosin may be available through local pharmacies via promotional pricing or generic alternatives.
Not addressed in the supplied prescribing information.
Online pharmacies and prescription discount websites may offer savings on Silodosin.
Not addressed in the supplied prescribing information.
Manufacturer assistance programs or patient support groups might provide financial aid or discount cards for eligible individuals.
Not addressed in the supplied prescribing information.
Generic Silodosin is typically less expensive than brand-name Silodosin.
Not addressed in the supplied prescribing information.
Generic formulations provide a more cost-effective treatment option than brand-name formulations.
Not addressed in the supplied prescribing information.
Generic medications are generally expected to be substantially cheaper than brand-name medications.
Not addressed in the supplied prescribing information.
Patent expiration for Silodosin is a key factor in the availability of generic versions and subsequent price reductions.
Not addressed in the supplied prescribing information.
Information regarding patent status and expiration dates for medications, including Silodosin, can be found through resources like DrugPatentWatch.com.
Not addressed in the supplied prescribing information.
Alternative medications for treating benign prostatic hyperplasia (BPH) include other alpha-blockers such as tamsulosin, alfuzosin, and terazosin.
Not addressed in the supplied prescribing information.
Alternative medications include 5-alpha reductase inhibitors.
Not addressed in the supplied prescribing information.
Generic tamsulosin is often available at competitive prices.
Not addressed in the supplied prescribing information.
Insurance coverage for Silodosin varies by plan.
Not addressed in the supplied prescribing information.
Many insurance providers cover Silodosin, particularly generic formulations, as a treatment for BPH.
Not addressed in the supplied prescribing information.
Patients should verify specific insurance plan benefits including copayments, deductibles, or prior authorization requirements.
Not addressed in the supplied prescribing information.
Silodosin works by selectively blocking alpha-1A adrenergic receptors.
Supplied label excerpt 12.1 states selective antagonist of alpha-1 adrenoreceptors; it does not explicitly state “alpha-1A” in the provided text.
Silodosin selective action is intended to minimize side effects like dizziness or low blood pressure associated with less selective alpha-blockers.
The label excerpt supports orthostatic effects and syncope risk (5.1) and provides data on orthostatic hypotension/dizziness, but does not claim intended minimization vs less selective alpha-blockers in the supplied text.
Contradictions
Low
AI Statement
Silodosin selective action is intended to minimize side effects like dizziness or low blood pressure associated with less selective alpha-blockers.
Label Reference
Label 5.1: “Postural hypotension, with or without symptoms (e.g., dizziness) may develop... there is potential for syncope.”
Low
AI Statement
The cost of a prescription for Silodosin can range from around $20 to over $100 for a 30-day supply.
Label Reference
Not assessable from supplied label (no pricing in excerpts).
Important Omissions
FDA-labeled dosing: recommended dose 8 mg orally once daily with a meal; dose reduction to 4 mg for moderate renal impairment; and contraindication with severe renal impairment.
Importance:
High
Contraindications: severe renal impairment (CCr < 30 mL/min), severe hepatic impairment (Child-Pugh > 10), and concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir).
Importance:
High
Key warning/precaution messaging: postural hypotension/syncope potential and counseling to avoid hazardous tasks/driving when initiating therapy.
Importance:
High
Drug interaction warning: do not use with strong CYP3A4 inhibitors; and do not use in combination with other alpha-blockers.
Importance:
High
Use in specific populations: pediatric not indicated; renal/hepatic impairment details.
Importance:
Moderate
Adverse reaction examples at ≥2% in trials (e.g., retrograde ejaculation, dizziness, orthostatic hypotension).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes substantial non-label financial/availability statements and omits multiple label-critical safety elements (contraindications, strong CYP3A4 interaction contraindications, dosing with meal and renal adjustment, and initiation counseling for orthostatic effects). These omissions could lead to inaccurate prescribing or unsafe use if the response were relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Response is dominated by unsupported pricing/coverage/patent/generic-availability claims and omits multiple label-critical prescribing/safety details (dose, contraindications, drug interactions, and precautions).
Suggested Improvement
Limit content to label-supported prescribing information. Include: indication for BPH (not hypertension), exact labeled dosing (8 mg once daily with a meal; reduce to 4 mg in moderate renal impairment), contraindications (severe renal/hepatic impairment; strong CYP3A4 inhibitors), orthostatic hypotension/syncope warning with initiation counseling, and key interaction restrictions (strong CYP3A4 inhibitors; other alpha-blockers). Remove or clearly separate non-label financial statements.